Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2024 report and make more profitable business decisions.
Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache, and shortness of breath. The predisposing factors include age, obesity, and hormone therapy. Treatment includes surgery, chemotherapy, and radiation therapy.
The Paroxysmal Nocturnal Hemoglobinuria drugs in development market research report provide comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Paroxysmal Nocturnal Hemoglobinuria | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 44 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Paroxysmal Nocturnal Hemoglobinuria therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Paroxysmal Nocturnal Hemoglobinuria pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Paroxysmal Nocturnal Hemoglobinuria treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ADARx Pharmaceuticals IncAevitas Therapeutics Inc
AffaMed Therapeutics US Inc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Amyndas Pharmaceuticals LLC
Apellis Pharmaceuticals Inc
Attune Pharmaceuticals
BioCryst Pharmaceuticals Inc
CANbridge Life Sciences Ltd
Chugai Pharmaceutical Co Ltd
Createrna Science and Technology Co Ltd
F. Hoffmann-La Roche Ltd
Homology Medicines Inc
ImmunAbs Inc
ISU ABXIS Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kira Pharmaceuticals
Lan-yi Therapeutics Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Pharmasyntez
Prestige BioPharma Ltd
Ra Pharmaceuticals Inc
Rallybio Corp
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Shanghai ComGen Biopharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Tianchen Biopharmaceutical (Suzhou) Co Ltd
Turgut Ilaclari AS
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Paroxysmal Nocturnal Hemoglobinuria reports